Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers
View Patent ↗A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.
1. A pharmaceutical composition comprising a mixture of the following components (a) and (b):
(a) a solid dispersion comprising a low-solubility drug and a matrix selected from the group consisting of polyethylene glycols, polyoxyethylene glycols, polyethylene-polypropylene glycol copolymers, polyethylene oxides, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene-vinyl alcohol copolymers, polyvinyl alcohol polyvinyl acetate copolymers, carboxylic acid-functionalized polymethacrylates, amine-functionalized polymethacrylates, xanthan gum, carrageenan, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxy methyl cellulose, chitosan, chitin, polydextrose, dextran and starch, wherein at least 60 wt % of said drug is amorphous; and
(b) an acidic concentration-enhancing polymer selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, and blends thereof.
2. The composition of claim 1 wherein the weight ratio of said drug to said matrix in said dispersion is less than 20.
3. The composition of claim 1 wherein said drug in said dispersion has a crystallization rate that is less than 90% of a crystallization rate of said drug in undispersed amorphous form.
4. The composition of claim 1 wherein said matrix is selected from the group consisting of xanthan gum, carrageenan, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxy methyl cellulose, chitosan, chitin, polydextrose, dextran and starch.
5. The composition of claim 1 wherein said dispersion is substantially homogeneous.
6. The composition of claim 1 wherein said dispersion is completely homogeneous.
7. The composition of claim 1 wherein said mixture is solid and wherein said concentration-enhancing polymer is suspended as a separate phase within said dispersion.
8. The composition of claim 1 wherein said mixture comprises particles of said dispersion and particles of said concentration enhancing polymer.
9. The composition of claim 8 wherein said mixture is formed by a method selected from the group consisting of dry granulation, wet granulation and a combination of dry and wet granulation.
10. The composition of claim 1 wherein said dispersion and said concentration-enhancing polymer are each in separate regions.
11. The composition of claim 1 wherein said drug is selected from the group consisting of antihypertensives, antianxiety agents, anticlotting agents, anticonvulsants, blood glucose-lowering agents, decongestants, antihistamines, antitussives, antineoplastics, beta blockers, anti-inflammatories, antipsychotic agents, cognitive enhancers, cholesterol reducing agents, antiobesity agents, autoimmune disorder agents, anti-impotence agents, antibacterial and antifungal agents, hypnotic agents, anti-Parkinsonism agents, anti-Alzheimer's disease agents, antibiotics, antidepressants, antiviral agents, anti-atherosclerotic agents, glycogen phosphorylase inhibitors, and cholesterol esterase transfer protein inhibitors.
12. A method of administering a drug comprising administering the pharmaceutical composition of claim 1 to a patient in need of said drug.
13. The method of claim 12 wherein said dispersion is administered separately from said concentration-enhancing polymer.
14. The method of 12 wherein said dispersion and said concentration-enhancing polymer are administered at approximately the same time.
15. The method of claim 12 wherein said dispersion and said concentration-enhancing polymer are present in a single dosage form.